Prof. John Kastelein, AMC, Amsterdam, The Netherlands comments on the results of the OSLER program with PCSK9 inhibitor evolocumab and provides a perspective on the therapeutic potential of PCSK9 inhibitors. Prof Kastelein is looking forward to the large scale clinical outcome trial FOURIER to confirm the results.
News • 16-3-2015
ACC 2015 PCSK9 inhibition with evolocumab halves the number of major CV outcomes in the open label OSLER extension programme. Treatment with evolocumab was safe, also at very low LDL-c levels.
3 minute education • 15-3-2015, ACC 2015, San Diego, Marc Sabatine, MD Boston
Dr. Marc S Sabatine MD, Boston, describes the very compelling results of OSLER studies and the potential for PCSK9 inhibition to reduce major cardiovascular events through robust LDL-c reduction
News • 17-3-2015
ACC 2015 Alirocumab Q4W can give sustained LDL-c lowering in some patients. Pooled analyses confirm safety of this PCSK9-antibody, also at very low LDL-c levels.
Literature • 19-3-2015 • Robinson et al., NEJM 2015
The ODYSSEY LONG TERM trial showed that alirocumab in addition to statins sustainably yielded a large reduction in LDL-c in patients at high CV risk and suggests that they experience fewer CV events.